Integrative Proteomic Characterization of Human Lung Adenocarcinoma.
Xu Jun-Yu,Zhang Chunchao,Wang Xiang,Zhai Linhui,Ma Yiming,Mao Yousheng,Qian Kun,Sun Changqing,Liu Zhiwei,Jiang Shangwen,Wang Minghui,Feng Lin,Zhao Lei,Liu Ping,Wang Bo,Zhao Xin,Xie Hui,Yang Xiaoyun,Zhao Liyuan,Chang Yafei,Jia Jingya,Wang Xijun,Zhang Yimin,Wang Yaru,Yang Yikun,Wu Zhixiang,Yang Longhai,Liu Bin,Zhao Teng,Ren Shengguo,Sun Aihua,Zhao Yang,Ying Wantao,Wang Fei,Wang Guangshun,Zhang Yi,Cheng Shujun,Qin Jun,Qian Xiaohong,Wang Yi,Li Jing,He Fuchu,Xiao Ting,Tan Minjia
Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the disease's biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD remain poorly understood. We carried out a comprehensive proteomics analysis of 103 cases of LUAD in Chinese patients. Integrative analysis of proteome, phosphoproteome, transcriptome, and whole-exome sequencing data revealed cancer-associated characteristics, such as tumor-associated protein variants, distinct proteomics features, and clinical outcomes in patients at an early stage or with EGFR and TP53 mutations. Proteome-based stratification of LUAD revealed three subtypes (S-I, S-II, and S-III) related to different clinical and molecular features. Further, we nominated potential drug targets and validated the plasma protein level of HSP 90β as a potential prognostic biomarker for LUAD in an independent cohort. Our integrative proteomics analysis enables a more comprehensive understanding of the molecular landscape of LUAD and offers an opportunity for more precise diagnosis and treatment.